Remediation led personally by Roberto L. Rivera — 45 years of cGMP experience, former Pfizer Senior Audit Manager. Root-cause analysis, a prioritized CAPA roadmap, and hands-on implementation that holds up under re-inspection — not a 150-page template your team can't execute.
A Warning Letter means the FDA has already documented violations of cGMP regulations and expects a written response within 15 working days. What you do in the weeks that follow determines whether this closes cleanly or escalates toward a Consent Decree, an import alert, or a facility shutdown.
The hard part isn't writing the response letter. It's building corrective actions that actually resolve the root cause — and proving to an investigator on re-inspection that they've been implemented and verified. Surface-level fixes that look good on paper are exactly what turn a Warning Letter into something far worse.
That's the work Roberto has done for four decades: standing on the other side of the table from FDA investigators, and knowing precisely what closes an observation for good.
"We responded to the letter, but the CAPAs didn't hold — and now the investigator is back and unimpressed."
This is the failure mode that escalates enforcement. A remediation that holds up under re-inspection is built on documented root-cause analysis and verified effectiveness — not a rewritten SOP. That verification is the core of every engagement.
Every engagement is scoped to the specific observations in your letter. Roberto leads each one personally, on-site, from day one to final verification.
A focused on-site assessment mapping each cited violation to the underlying systems, with regulatory mapping to FDA 21 CFR 210/211, 820, and applicable international standards.
Structured root-cause investigation for each observation — because a CAPA that treats the symptom rather than the cause is what fails on re-inspection.
A concrete, sequenced remediation plan your team can implement without halting production — sorted by regulatory risk, not padded into a generic template.
Hands-on leadership through implementation across aseptic operations, data integrity, pharmaceutical operations, and biologics manufacturing.
Verification that each corrective action is implemented and effective — the documented proof an investigator looks for on re-inspection.
A pre-inspection mock audit and walkthrough so you are not surprised by what the investigator finds — because Roberto found it first.
Within one business day of your inquiry, Roberto reviews the Warning Letter and the cited observations with you. A mutual NDA can be executed before any detail is shared. Most engagements are scoped and under way within two weeks.
Roberto assesses each cited system on-site, identifies the true root cause, and separates what the FDA named from the adjacent gaps that would surface next.
A prioritized CAPA plan is built with your team, along with support for the formal written FDA response — acknowledging each violation with corrective actions and realistic timelines.
Roberto leads implementation on-site, with weekly regulatory progress reporting, keeping the work realistic against your production constraints.
Each corrective action is verified for effectiveness and documented, closing with a mock inspection so your facility is ready when the investigator returns.
You work directly with Roberto L. Rivera — not a rotating team of junior associates. A former Pfizer Senior Audit Manager with 45 years across the world's most regulated facilities, who has personally led remediation for Warning Letters and Consent Decrees across five global regulatory regions. Remediation engagements are backed by the Zero Warning Letter Guarantee, subject to the terms of the engagement letter.
The FDA expects a written response within 15 working days of receipt, acknowledging each violation, describing the corrective actions taken or planned, and giving a realistic timeline. Roberto replies to remediation inquiries within one business day and can typically scope an engagement within two weeks, so your CAPA work begins without delay.
An on-site gap assessment against the cited observations, root-cause analysis, a prioritized CAPA plan, hands-on implementation leadership, and verification that each corrective action holds up under re-inspection. Roberto leads the engagement personally rather than delegating it.
Yes. Roberto has led crisis-level remediation for both FDA Warning Letters and Consent Decrees, as well as comparable enforcement actions from international regulators, across aseptic operations, data integrity, pharmaceutical operations, and biologics manufacturing.
You work directly with a former Pfizer Senior Audit Manager with 45 years of cGMP experience and seven ASQ certifications — not a rotating team of junior consultants. Every CAPA Roberto has closed has held up under subsequent regulatory inspection, and remediation engagements are backed by the Zero Warning Letter Guarantee, subject to the engagement letter.